long intergenic non-protein coding RNA 1342Genealiases: []
Q-omics provides the consensus-scored LINC01342 profile across patient tissues and cancer cell-line models. LINC01342 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01342 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LINC01342 RNA expression shows 13,813 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, KIRC, and ESCA as cancer lineages where LINC01342 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01342 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01342 survival associations across molecular data types. LINC01342 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01342 RNA expression–survival associations across cancer types. High LINC01342 expression shows unfavorable associations in LGG, but favorable associations in HNSC, UCS, SKCM, KICH and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01342 RNA expression.
This table summarizes LINC01342 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01342. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01342 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in COAD, STAD and CHOL. The KIRC box plot shows higher LINC01342 RNA expression in normal versus tumor tissue (log2 FC = −0.217, t-test p < 0.001).
This table shows molecular features associated with LINC01342 in patient tissues and cancer cell lines. In patient samples, LINC01342 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
